-
Bayer earnings preview: Recent focus on asundexian momentum ahead of Q4 results
-
Bayer reports phase I results for prostate cancer therapy
-
Bayer's XOFIGO plus enzalutamide reduces death risk by 24% in prostate cancer
-
Bayer proposes $10.5 billion to settle Roundup cancer lawsuits - Bloomberg
-
Bayer's asundexian reduces stroke risk by 26% in phase III trial
-
Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR40 at BMO Capital
-
Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR55 at BofA Securities
-
Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR55 at Morgan Stanley
-
Bayer AG (BAYN:GR) (BAYRY) PT Raised at BMO Capital as 'Positive SCOTUS Outcome Probability Improves '
-
Morgan Stanley Upgrades Bayer AG (BAYN:GR) (BAYRY) to Overweight
-
Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR35 at Goldman Sachs
-
Kepler Cheuvreux Upgrades Bayer AG (BAYN:GR) (BAYRY) to Buy
-
Goldman Sachs Upgrades Bayer AG (BAYN:GR) (BAYRY) to Buy
-
Bayer AG (BAYGN) announces FDA approval for Jivi
-
BofA Securities Upgrades Bayer AG (BAYN:GR) (BAYRY) to Buy
-
Bayer AG (BAYN:GR) (BAYRY) PT Lowered to EUR25 at CFRA
-
Bayer AG (BAYN:GR) (BAYRY) PT Lowered to EUR26 at BMO Capital
-
BofA Securities Upgrades Bayer AG (BAYN:GR) (BAYRY) to Neutral

